Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.
Eli Lilly's Alzheimer's drug, Kisunla, received FDA approval, expected to generate billions. However, the stock didn't surge as the approval was already priced in. The company's focus and investor excitement are more on its GLP-1 treatments for obesity and diabetes, indicating future growth potential beyond Kisunla.
Reference News
Eli Lilly's Alzheimer's Drug Obtains FDA Approval. Here's Why the Stock Isn't Taking Off.
Eli Lilly's Alzheimer's drug, Kisunla, received FDA approval, expected to generate billions. However, the stock didn't surge as the approval was already priced in. The company's focus and investor excitement are more on its GLP-1 treatments for obesity and diabetes, indicating future growth potential beyond Kisunla.